January 9, 2014 | Israeli pharmaceutical giant Teva Pharmaceutical Industries has made an offer to acquire American biotechnology company NuPathe for $149 million. NuPathe is developing treatments for various neurological disorders and has a market cap of $100 million.
Related posts
Israeli AI Safety Tool Among TIME’S Best Inventions For 2024
October 31, 2024
TAU Team Discovers Mechanism To Eliminate Cancerous Tumors
October 30, 2024
Ashdod Port Investing In Startups As Part Of Innovation Strategy
October 29, 2024
BGU Develops Fast Fact Checking Via News Sources Not People
October 28, 2024
Facebook comments